PR Web (press release) |
ECOG-ACRIN Opens Clinical Trial Investigating Ibrutinib-Rituximab …
PR Web (press release) Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912. Share on Twitter Share on Facebook Share on Google+ Share … |
Immune drug helps patients with frequently relapsing kidney diseaseNephrologyNews.comRituximab can effectively and safely prevent recurrences and reduce the need for immunosuppression in frequently-relapsing idiopathic nephrotic syndrome, according to …
|
OriGene Developing Antibodies for SISCAPA Assays with NCI Contract
GenomeWeb NEW YORK (GenomeWeb News) – OriGene Technologies announced that it has received a contract from the National Cancer Institute to develop high affinity anti-peptide antibodies for SISCAPA assays. SISCAPA, short for Stable Isotope Standards and … |
|
Hi-res view shows HIV ‘pools’ in the gut
Futurity: Research News The finding of HIV transfer via free pools of free virus offers hope that treatment with protein-based drugs, such as antibodies, could be an effective means of augmenting or replacing current treatment regimens that use small-molecule antiretroviral … |
Biologics and Biosimilars World MarketsSacramento Bee… 6.43.4 Genotropin (somatropin) 231 6.43.5 Herceptin (trastuzumab) 232 6.43.6 Humira (adalimumab) 232 6.43.7 Neulasta (pegfilgrastim) 233 6.43.8 Neupogen (filgrastim) 233 6.43.9 Remicade (inflixim…
Multiple Sclerosis — KOL Insight and Consensus Outlook ModulesSYS-CON Media (press release)Rebif (interferon beta-1a; Merck Serono) forecast2.14.Extavia (interferon beta-1b; Novartis) forecast2.15.Lemtrada (alemtuzumab; Genzyme/Sanofi) forecast2.16.La…
MMRGlobal receives cancer-fighting anti-CD20 monoclonal antibodies patent in …Pharmaceutical Business ReviewThis is the fourth country to issue this patent as a result of the Expedited Patent Allowance Program which follows the issuance of US patents…
|
Frontier Pharma: Systemic Lupus Erythematosus – Identifying and …
PR Newswire (press release) … Benlysta (belimumab), generated sales of $111m in 2012, there is little evidence that the drug’s performance is significantly superior to other B-cell targeted therapies such as Rituxan (rituximab), which is often used off-license to treat … |
|
What’s Good For Baby Camels Coul Be Good For Human Skin
WLRN Scientists at Shihab’s company in Amman, called MONOJO, have been analyzing the antibodies in camel’s milk. These proteins help fight off infections, latching onto foreign pathogens and telling the body’s immune system: “intruder alert.” They typically … |
|
Immune Drug Helps Relapsing Kidney Disease
Ivanhoe (Ivanhoe Newswire) –A recent study shows that in patients with a frequently-relapsing form of kidney disease, relapses decreased approximately five-fold for at least one year after patients took a single dose of rituximab. For many patients with a … |